Autoplaque vs uOmnispace.MR

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

uOmnispace.MR

by Shanghai United Imaging Healthcare Co., Ltd.

AI Verdict

Autoplaque is an AI-powered tool specifically designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. In contrast, uOmnispace.MR provides a broader AI-driven platform for comprehensive magnetic resonance (MR) image analysis, supporting diverse clinical applications including cardiac function. While both contribute to cardiology AI, their fundamental difference in imaging modality (CT vs. MR) and specific analytical targets makes them suitable for distinct diagnostic pathways.

Choose Autoplaque if…

Choose Autoplaque if your primary need is precise, AI-powered quantitative analysis of coronary plaques and luminal stenoses specifically from CT angiography images. This tool is ideal for clinicians focused on detailed heart attack risk prediction and guiding treatment strategies based on coronary artery disease assessment.

View Autoplaque →

Choose uOmnispace.MR if…

Choose uOmnispace.MR if you require a versatile, AI-powered platform for comprehensive magnetic resonance (MR) image analysis across multiple clinical applications, including brain, breast, and cardiac imaging. This tool is best suited for environments needing advanced post-processing, AI-driven segmentation, and remote multi-user access for diverse MR studies.

View uOmnispace.MR →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	uOmnispace.MR
Pricing	Unknown	Contact for pricing
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	Software-only medical device; can run standalone or integrated with other cleared applications on standard off-the-shelf PCs; supports remote multi-user access on a network. The broader uOmnispace platform is available as SaaS, on-premise, or hybrid.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

uOmnispace.MR

Tool B offers superior deployment flexibility, including standalone, integrated, SaaS, on-premise, and hybrid options, along with explicit support for remote multi-user access on a network. This adaptability makes it more versatile for diverse clinical environments and collaborative workflows compared to Tool A's workstation-based deployment.

Clinical Value

Autoplaque

Autoplaque provides highly specialized and clinically validated AI-powered quantitative analysis of coronary plaques from CT angiography, directly aiding in heart attack risk prediction and treatment guidance. This focused application addresses a critical public health issue with demonstrated clinical impact and extensive validation. While Tool B offers broader utility across multiple MR applications, Tool A's concentrated value in a high-stakes area gives it an edge.

Pricing & Value

Tie

Both Autoplaque and uOmnispace.MR have undisclosed pricing, making it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value for money. While Tool B mentions a subscription model for its broader platform, specific pricing for uOmnispace.MR is not publicly available.

Enterprise Readiness

uOmnispace.MR

Tool B explicitly states HIPAA compliance and offers a Business Associate Agreement, alongside highly flexible deployment options including SaaS, on-premise, and hybrid models with remote multi-user access. This comprehensive approach to compliance and infrastructure adaptability makes it significantly more enterprise-ready than Tool A, which is workstation-based and lacks specified compliance details.

Innovation

Autoplaque

Autoplaque's innovation lies in its highly specialized and validated application of AI for quantitative coronary plaque analysis, directly contributing to heart attack risk prediction. This focused, high-impact use of AI for a critical clinical outcome demonstrates a significant advancement in preventative cardiology. While Tool B offers broad AI integration across various MR applications, Autoplaque's specific predictive capability is a more distinct innovation.

Support & Docs

uOmnispace.MR

While specific documentation is not publicly detailed for either, Tool B is offered by Shanghai United Imaging Healthcare Co., Ltd., a global medical imaging company that explicitly provides training, monitoring, maintenance, and troubleshooting services for its products. This indicates a more formalized and comprehensive support structure typical of a commercial vendor compared to Tool A, which originates from an academic institution.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	uOmnispace.MR
Name	Autoplaque	uOmnispace.MR
Company	Cedars-Sinai Medical Center: AIM	Shanghai United Imaging Healthcare Co., Ltd.
Primary Imaging Modality	CT angiography images	Magnetic Resonance (MR) images
Core Analytical Focus	Quantitative analysis of coronary plaques and luminal stenoses	Comprehensive MR image analysis, supporting diverse clinical applications including brain, breast, and cardiac imaging
Specific Cardiac Analysis Feature	AI-powered quantitative analysis of atherosclerotic plaque; Measurement of luminal stenoses; Automated vessel, plaque, and lumen segmentation	AI-driven cardiac ventricular segmentation; Cardiac function analysis

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and uOmnispace.MR.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What imaging modalities do these tools support?

Autoplaque is specifically designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. In contrast, uOmnispace.MR is an AI-powered software for comprehensive magnetic resonance (MR) image analysis, supporting various MR applications including brain, breast, and cardiac imaging.

What are the primary clinical applications for each tool in cardiology?

Autoplaque focuses on AI-powered quantitative analysis of atherosclerotic plaque and measurement of luminal stenoses from CT angiography images to aid in heart attack risk prediction and treatment guidance. uOmnispace.MR offers AI-driven cardiac ventricular segmentation and cardiac function analysis from MR images, among other features.

Do these tools offer capabilities beyond cardiology?

Autoplaque is primarily focused on the analysis of coronary anatomy and pathology from CT angiographic images, specifically for cardiology applications. uOmnispace.MR has a broader scope, supporting diverse clinical applications including brain, breast, and cardiac imaging, as well as neurology and oncology.

What specific types of plaque analysis does Autoplaque provide?

Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque, including detection and characterization of coronary artery plaque, and measurement of luminal stenoses. It also offers automated vessel, plaque, and lumen segmentation, which can be reviewed and edited by a clinician.